Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
University of Illinois at Chicago
Kura Oncology, Inc.
University of Alabama at Birmingham
Faron Pharmaceuticals Ltd
Dana-Farber Cancer Institute
Massachusetts General Hospital
CellCentric Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AbbVie
OHSU Knight Cancer Institute
Prelude Therapeutics
First Affiliated Hospital of Zhejiang University
AbbVie